Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology

Bibliographic Details
Title: Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology
Authors: Fabiola Alonso, Ángel L.M. Martín de Francisco, Pilar Auñón, Clara García-Carro, Patricia García, Eduardo Gutiérrez, Manuel Mcía, Luis F. Quintana, Borja Quiroga, María José Soler, Isidro Torregrosa
Source: Nefrología (English Edition), Vol 43, Iss 5, Pp 622-635 (2023)
Publisher Information: Elsevier, 2023.
Publication Year: 2023
Collection: LCC:Diseases of the genitourinary system. Urology
Subject Terms: Insuficiencia renal aguda, Nefritis tubulointersticial aguda, Inhibidores del check-point, Inmunoterapia, Efectos inmunes renales adversos, Trasplante renal, Diseases of the genitourinary system. Urology, RC870-923
More Details: The most widely used approach in the immunotherapy treatment of cancer is the administration of monoclonal antibodies directed against regulatory molecules of immune control that inhibit the activation of T cells, the so-called check point inhibitors (ICI). ICI nephrotoxicity epidemiology and pathology; its diagnosis with or without kidney biopsy; the type and duration of treatment; the possibility of rechallenging after kidney damage; and its indication in patients with cancer and renal transplantation are certainly controversial. In the absence of definitive studies, this document is intended to specify some recommendations agreed by the group of Onconephrology experts of the Spanish Society of Nephrology in those areas related to ICI nephrotoxicity, in order to help decision-making in daily clinical practice in Onconephrology consultations. Resumen: El enfoque más utilizado en el tratamiento inmunoterápico del cáncer es la administración de anticuerpos monoclonales dirigidos contra moléculas reguladoras del control inmunitario que inhiben la activación de las células T, los llamados inhibidores del Check-Point (ICP). La epidemiología y patología de la nefrotoxicidad por los ICP; su diagnóstico con o sin biopsia renal; el tipo y la duración del tratamiento; la posibilidad de retratar después del daño renal; y su indicación en pacientes con cáncer y trasplante renal son ciertamente controvertidas. En ausencia de estudios definitivos, este documento está destinado a concretar unas recomendaciones consensuadas por el grupo de expertos de Onconefrología de la S.E.N en aquellas áreas relacionadas con la nefrotoxicidad por los ICP, con la finalidad de ayudar en la toma de decisiones en la práctica clínica diaria de las consultas de Onconefrología.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2013-2514
Relation: http://www.sciencedirect.com/science/article/pii/S2013251423001700; https://doaj.org/toc/2013-2514
DOI: 10.1016/j.nefroe.2023.11.001
Access URL: https://doaj.org/article/0a59c8c541e74dcd80642d12401a4c78
Accession Number: edsdoj.0a59c8c541e74dcd80642d12401a4c78
Database: Directory of Open Access Journals
More Details
ISSN:20132514
DOI:10.1016/j.nefroe.2023.11.001
Published in:Nefrología (English Edition)
Language:English